Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Up 18.7% in December

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 10,800 shares, a growth of 18.7% from the November 30th total of 9,100 shares. Approximately 1.7% of the company’s stock are short sold. Based on an average trading volume of 18,700 shares, the days-to-cover ratio is currently 0.6 days.

Titan Pharmaceuticals Stock Performance

NASDAQ:TTNP opened at $3.40 on Tuesday. The company’s 50-day simple moving average is $3.80 and its 200-day simple moving average is $5.04. Titan Pharmaceuticals has a fifty-two week low of $3.12 and a fifty-two week high of $14.80.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Titan Pharmaceuticals in a research report on Friday. They issued a “sell” rating for the company.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.